ReachMD CME

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/does-your-patient-have-pbc/29108/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

CME credits: 0.25 Valid until: 31-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/empowering-choices-navigating-early-stage-hr-her2-breast-cancer-with-cdk46-inhibition/26643/ Hormone receptor-positive, HER2-negative cancer is the most common subtype of breast cancer. Initial treatment consists of surgery with or without radiotherapy or chemoradiotherapy, followed by adjuvant endocrine therapy for 5 to 10 years. Although endocrine therapy improves outcomes in these patients, recurrence is high (40% to 60% of patients). In disease with no BRCA mutation, treatment intensification by adding a CDK4/6 inhibitor to endocrine therapy has been shown to improve survival outcomes in high-risk disease. This activity explores the role of CDK4/6 inhibitors in HR-positive, HER2-negative early breast cancer in a patient case vignette, with an emphasis on shared decision-making.

CME credits: 0.25 Valid until: 31-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/empowering-choices-navigating-early-stage-hr-her2-breast-cancer/26643/ Hormone receptor-positive, HER2-negative cancer is the most common subtype of breast cancer. Initial treatment consists of surgery with or without radiotherapy or chemoradiotherapy, followed by adjuvant endocrine therapy for 5 to 10 years. Although endocrine therapy improves outcomes in these patients, recurrence is high (40% to 60% of patients). In disease with no BRCA mutation, treatment intensification by adding a CDK4/6 inhibitor to endocrine therapy has been shown to improve survival outcomes in high-risk disease. This activity explores the role of CDK4/6 inhibitors in HR-positive, HER2-negative early breast cancer in a patient case vignette, with an emphasis on shared decision-making.

CME credits: 1.00 Valid until: 17-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/pulmonary-hypertension-for-advanced-practice-providers-risk-stratification-and-diagnosis-to-enhance-quality-of-care-and-outcomes/27146/ This program focuses on early symptom identification and timely diagnosis in patients with pulmonary hypertension (PH). Learn how appropriate risk stratification can facilitate the effective management of PH. Our experts also stress the importance of asking the right questions and offer strategies for achieving well-rounded communication with patients and their caregivers.

CME credits: 0.25 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/patient-centric-approaches-to-optimizing-outcomes-in-aad-case-review/26713/ Early diagnosis and management of agitation in Alzheimer’s disease (AAD) is part of a comprehensive treatment plan. How can you help caregivers recognize subtle signs of AAD to facility early treatment? Our experts have the answers you need!

CME credits: 1.00 Valid until: 11-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/updates-from-the-7th-world-symposium-task-force/24597/ The 7th World Symposium Task Force on Pulmonary Hypertension focused on the standard of care, best practices, and emerging clinical data in the treatment of pulmonary hypertension (PH). For the first time, the 2024 Symposium started with patients’ perspectives, acknowledging the respect and importance that should be given to patients’ priorities. The translational aspects of modern pulmonary vascular research were highlighted, as were transplantation, bridging and support technologies, palliative care, management of pregnant women with PH, specificities of pediatric care, and the benefits of emerging multimodality imaging techniques and novel technologies. Tune in to get the details and improve care for your patients today!

CME credits: 1.00 Valid until: 11-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/advancing-cystic-fibrosis-addressing-disparities-challenging-perceptions-and-innovating-patient-centered-care/24487/ Cystic Fibrosis (CF) care faces challenges from health disparities, limited access, and unintended bias, affecting patient outcomes. This CME program aims to equip healthcare professionals with the skills needed to overcome these barriers and provide equitable care for all CF patients. It covers telehealth strategies, best practices for transitioning patients from pediatric to adult care, and managing co-morbidities. The program also explores how evolving treatments impact patient outcomes.

CME credits: 1.00 Valid until: 11-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/bridging-distances-in-pah-bringing-best-practices-to-the-people-through-telemonitoring/24051/ Pulmonary Arterial Hypertension (PAH) requires a personalized, multidisciplinary approach, which is often lacking in remote regions due to limited access to specialized care and resources. The scarcity of specialized PH centers forces reliance on general practitioners, further hampered by geographic isolation and constrained resources. These limitations make it difficult for healthcare providers to stay updated on new treatments, guidelines, and clinical trial data. To address these gaps, a strategic initiative is needed to enhance early detection, deliver insights on novel therapies, and promote multidisciplinary care through telementoring, aiming to improve PAH management in underserved rural areas.

CME credits: 1.00 Valid until: 04-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/bringing-treatment-into-focus-biomarker-driven-first-line-therapy-for-metastatic-gastricgej-cancers/26719/ This educational activity delves into biomarker-driven strategies for first-line therapy in metastatic gastric and gastroesophageal junction (GEJ) cancers. Participants will explore the latest clinical trial data and emerging biomarkers that guide treatment decisions. Our experts emphasize selecting optimal therapies tailored to patient-specific factors and offer strategies for managing treatment-related adverse effects. Tune in to enhance treatment efficacy and patient outcomes for your patients with metastatic gastric/GEJ cancers.

CME credits: 0.25 Valid until: 04-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/navigating-copd-from-symptom-recognition-to-emerging-treatment-strategies/26928/ Listen in as Farrukh Abbas, MD, FCCP, and Megan Conroy, MD, MAEd, FCCP, discuss the role of the care team in COPD diagnosis, recent changes in classifications and updates to the GOLD guidelines, how triple-inhaler therapies and biologics can be used to treat patients with COPD, and more. Since the time of this recording, the FDA has recently approved dupilumab as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) with type 2 inflammation.

CME credits: 0.75 Valid until: 02-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-evolving-role-of-met-tkis-in-nsclc/17986/ The MET pathway can be activated by MET exon 14 skipping mutations, gene amplification, or overexpression. Mutations within this pathway carry a poor prognosis for patients with non-small cell lung cancer (NSCLC). Early studies of MET tyrosine kinase inhibitors (TKIs) demonstrated limited clinical benefit; however, newer selective MET TKIs, such as capmatinib and tepotinib, have improved efficacy and acceptable safety profiles. In this activity, our experts assess the role of the role of MET gene aberrations in NSCLC and optimal testing modalities, as well as the clinical evidence supporting the use of MET TKIs and the potential role of these therapies in other subsets of disease.

CME credits: 0.25 Valid until: 30-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-redefining-treatment-across-the-spectrum-of-hrher2-expressing-metastatic-breast-cancer/26625/ This Chairperson’s Perspective will provide an in-depth look at ADC-directed therapies for HR+/HER2-expressing metastatic breast cancer. Participants will explore current treatment options, emerging data, and best practices for selecting and sequencing therapies. The session will also cover strategies for managing adverse events associated with these treatments to optimize patient outcomes. Designed for healthcare professionals, this program aims to enhance clinical decision-making in the evolving landscape of metastatic breast cancer care.

CME credits: 1.00 Valid until: 25-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/mastering-the-complexity-of-aml-treatment-a-multidimensional-approach-to-diagnosis-therapy-and-side-effect-management/26723/ While the expanding arsenal of therapies available for patients with AML allows practitioners to further hone treatment and individualize care, the complexity of treatment decision-making requires careful consideration of potential risks and benefits of each treatment option. This real-world, case-based program will provide a format for community hematology-oncologists to hear current updates on the latest targeted therapies in AML and engage in pointed, practical discussions on how to best integrate these data into current and local AML treatment paradigms.

CME credits: 0.25 Valid until: 25-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/implementing-a-multidisciplinary-approach-to-heart-failure-patient-identification-and-treatment-using-novel-device-therapy/16191/ Despite guideline-directed medical therapy, many patients with heart failure will continue to develop worsening symptoms and diminishing quality of life. Baroflex activation therapy (BAT) may be a treatment option for patients with heart failure with reduced ejection fraction. Data show clinical benefit with this treatment approach including long-term symptom improvement and reduction in all-cause death. To ensure optimal outcomes with BAT, a multidisciplinary approach is necessary. In this activity, expert faculty review the rationale for BAT therapy, the supporting clinical data, the surgical procedure for the BAT device, and best practices for optimizing a multidisciplinary approach.

CME credits: 1.00 Valid until: 24-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/noncovalent-btk-inhibitors-new-targeted-options-for-relapsed-or-refractory-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma/24362/ This program addresses the educational needs for relapsed or refractory (R/R) B-cell leukemias and lymphomas, particularly chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and reveals crucial practice gaps. Key challenges include managing poor treatment responses and patient health deterioration, necessitating therapies that extend survival and improve quality of life. Noncovalent Bruton’s tyrosine kinase inhibitors (ncBTKi) show promise in these cases, but clinicians need updated knowledge on their use, including response rates and management of associated toxicities. Additionally, the evolving landscape of B-cell lymphoma therapies complicates treatment choices, requiring expert guidance on individualized therapy selection and sequencing.

CME credits: 0.25 Valid until: 18-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/how-antibody-based-therapies-are-revolutionizing-its-management/26371/ Warm autoimmune hemolytic anemia (wAIHA) is a rare condition characterized by the premature destruction of red blood cells mainly by pathogenic IgG optimally active at 37oC. Innovative targeted therapies to address wAIHA are emerging, and many are likely to greatly improve patient outcomes when they reach the clinic. Join Drs. Caroline Piatek and Irina Murakhovskaya as they discuss in detail current and emerging non-antibody and monoclonal antibody therapies for wAIHA and how each has the potential to dramatically improve the treatment landscape for wAIHA.

CME credits: 0.75 Valid until: 15-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/level-up-your-skills-tailoring-management-of-hf/27021/ Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates of comorbidities such as diabetes and chronic kidney disease. Despite advances in medical science, gaps persist in the identification, diagnosis, and management of heart failure among healthcare providers, particularly in the cardiology and primary care settings. This accredited microlearning program highlights key topics in HF in video episodes that are 7-10 minutes each. Each microlearning features peer-to-peer interviews or panel discussions with leading experts in the following episodes: (1) Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression; (2) Partnering with Patients: Building Effective Communication and Support in HF Care; (3) A Practical Guide to Prescribing in HF; (4) HF Management for Patients with Comorbid Conditions; (5) Level Up Your Skills: Tailoring Management of HF.

CME credits: 0.75 Valid until: 15-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/hf-management-for-patients-with-comorbid-conditions/27020/ Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates of comorbidities such as diabetes and chronic kidney disease. Despite advances in medical science, gaps persist in the identification, diagnosis, and management of heart failure among healthcare providers, particularly in the cardiology and primary care settings. This accredited microlearning program highlights key topics in HF in video episodes that are 7-10 minutes each. Each microlearning features peer-to-peer interviews or panel discussions with leading experts in the following episodes: (1) Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression; (2) Partnering with Patients: Building Effective Communication and Support in HF Care; (3) A Practical Guide to Prescribing in HF; (4) HF Management for Patients with Comorbid Conditions; (5) Level Up Your Skills: Tailoring Management of HF.

CME credits: 0.75 Valid until: 15-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/a-practical-guide-to-prescribing-in-hf/27019/ Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates of comorbidities such as diabetes and chronic kidney disease. Despite advances in medical science, gaps persist in the identification, diagnosis, and management of heart failure among healthcare providers, particularly in the cardiology and primary care settings. This accredited microlearning program highlights key topics in HF in video episodes that are 7-10 minutes each. Each microlearning features peer-to-peer interviews or panel discussions with leading experts in the following episodes: (1) Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression; (2) Partnering with Patients: Building Effective Communication and Support in HF Care; (3) A Practical Guide to Prescribing in HF; (4) HF Management for Patients with Comorbid Conditions; (5) Level Up Your Skills: Tailoring Management of HF.

CME credits: 0.75 Valid until: 15-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/partnering-with-patients-building-effective-communication-and-support-in-hf-care/27018/ Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates of comorbidities such as diabetes and chronic kidney disease. Despite advances in medical science, gaps persist in the identification, diagnosis, and management of heart failure among healthcare providers, particularly in the cardiology and primary care settings. This accredited microlearning program highlights key topics in HF in video episodes that are 7-10 minutes each. Each microlearning features peer-to-peer interviews or panel discussions with leading experts in the following episodes: (1) Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression; (2) Partnering with Patients: Building Effective Communication and Support in HF Care; (3) A Practical Guide to Prescribing in HF; (4) HF Management for Patients with Comorbid Conditions; (5) Level Up Your Skills: Tailoring Management of HF.